LUMOS-DIAGNOSTICS
6.10.2020 23:52:11 CEST | Business Wire | Press release
Lumos Diagnostics , a rapid point-of-care diagnostics company, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
The funding will enable Lumos, headquartered in Melbourne, to continue to build its high-growth rapid diagnostics business in the U.S., including expanding manufacturing operations in California and Florida and continuing commercial growth of its FebriDx® product, a world-first finger prick blood test that can indicate if a person has a bacterial or viral infection within 10 minutes.
The capital was raised from a combination of institutional funds, including Perennial Value and Ellerston Capital, and sophisticated investors, many of whom have backed Lumos through previous capital raises. It follows on from a successful Series A raise in early 2020, led by Planet Innovation , a Melbourne-based healthcare innovation company.
“Lumos has built a strong foundation over the past few years, and this funding will enable us to accelerate our growth plan,” said Sam Lanyon, executive chair of Lumos Diagnostics. “We’re delighted that investors recognize how unique Lumos is with its suite of rapid diagnostic digital solutions coupled with high-impact and globally relevant proprietary products such as FebriDx.”
David Keelan, Portfolio Manager at Ellerston Capital and a first-time Lumos investor, said: “I’m really excited by Lumos’s potential. Rapid diagnostics is a developing sector internationally, and to have a really strong and growing service business, complemented by a product business with huge potential – it was too good an investment to pass up.”
Ryan Sohn, Deputy Portfolio Manager at Perennial Value, was introduced to Lumos Diagnostics through Planet Innovation (PI), where he is also an investor. “Through PI, I’ve been able to track Lumos’s substantial growth over the past few years. It’s a company with great ambition and a great team behind it, and I’m excited to be a part of this next phase of growth as it prepares for an IPO next year,” Ryan said.
While many businesses have been negatively impacted by the devastating global impacts of the COVID-19 crisis, Lumos was well positioned to quickly respond and has subsequently experienced growth across both its service and product businesses. On the service side, Lumos has secured several contracts to develop and manufacture next generation rapid SARS-CoV-2 tests. On the product side, the UK’s National Institute of Health Research (NIHR) has demonstrated real-world use of the FebriDx test as a frontline triage tool to help healthcare workers manage suspected COVID-19 infected patients. The FebriDx test was featured in a UK Medtech Innovation Briefing (MIB) , addressing the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises. Also, FebriDx may be used as an important risk assessment tool for safe workplaces and is currently being piloted in aged care and other professional use settings continuing to operate during the pandemic.
Robert Sambursky, MD, president and chief executive officer for Lumos Diagnostics, said the capital raise would enable Lumos to expand its commercial operations dedicated to both the continued development of rapid point-of-care diagnostics and meet the need for innovative testing solutions to help address the global COVID-19 pandemic.
“The unique ability of the FebriDx test to identify patients as viral or bacterial within 10 minutes helps guide clinical decision making – whether that is isolation for those identified as having a virus, antibiotic prescriptions for bacterial infections, or simply reassurance that an infection is not present. These actionable results make FebriDx the ideal front-line triage test for patients presenting with acute respiratory illness symptoms (sore throat, cough, shortness of breath) consistent with COVID-19 and an ideal tool for rapid deployment in any future pandemics,” Sambursky said.
While FebriDx is not yet commercially available in the U.S., Lumos Diagnostics has both ongoing and historic prospective, multicenter U.S. clinical trials and anticipates U.S. Food and Drug Administration (FDA) clearance.
Blackpeak Capital acted as Financial Advisor to Lumos and Joint Lead Manager for the raising alongside Canaccord Genuity.
About Lumos Diagnostics
Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs.
Lumos’s current portfolio of tests includes:
- FebriDx®, an all-in-one, disposable, 10-minute, fingerstick blood test that differentiates viral from bacterial acute respiratory infections (ARI).
- COV-ID™; the Diagnostic Kit (Colloidal Gold) for IgG/IgM Antibody to SARS-CoV-2, a rapid and easy-to-use serology test for the qualitative detection of antibodies to SARS-CoV-2 virus in patients suspected of a history of COVID-19 infection.
Both the FebriDx and COV-ID tests are CE marked for sale in Europe. FebriDx is also registered or licensed with the following other health authorities: Health Canada, Australia TGA, Saudi Arabia FDA, Pakistan DRAP, Singapore HSA, and Malaysia MoH. COV-ID is available in specific global markets in compliance with country requirements. The FebriDx test has not received U.S. FDA clearance and is not commercially available in the United States. For more information on Lumos Diagnostics, visit lumosdiagnostics.com , and for more information on FebriDx, visit febridx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release
The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f
IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 17:00:00 CET | Press release
IQM quantum computers already run at leading supercomputing centers, including Oak Ridge National Laboratory (ORNL), VTT Technical Research Centre of Finland, the Leibniz Supercomputing Centre (LRZ) and CINECA, with users reaching them through Slurm. IQM supports NVIDIA’s investment in making quantum processors a schedulable resource in supercomputing centers by integrating IQM quantum computers with Slurm. IQM’s partner MQSC (Munich Quantum Software Company) has demonstrated the MQSC Orchestrator scheduling IQM systems through the new Slurm capability. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making q
What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release
We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live
Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release
Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
